NR2F1和mTORC1提供了黑色素瘤休眠期和治疗耐药性之间的桥梁
Narsimha Mamidi1,2, Swadesh K Das1,2,3, Paul B Fisher1,2,3
1Department of Cellular, Molecular and Genetic Medicine.
The Journal of clinical investigation
|September 16, 2025
概括
耐药黑色素瘤细胞通过激活NR2F1.1,抵抗治疗. 结合BRAF/MEK抑制剂与拉巴胺素,可向这些细胞,为皮肤黑色素瘤患者提供新的策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 皮肤病学 皮肤病学
背景情况:
- 皮肤黑色素瘤 (CM) 表现出侵略性行为和高转移潜力,导致预后不佳.
- 在CM中,BRAF突变很普遍,BRAF/MEK抑制剂 (BRAFi+MEKi) 治疗显示有效.
- 治疗反应的持久性受到耐药残留细胞的限制,导致复发.
研究的目的:
- 研究NR2F1在黑色素瘤治疗耐药性的作用.
- 探索NR2F1对黑色素瘤扩散,入侵和治疗疗效的影响.
- 评估针对NR2F1和mTORC1信号的组合疗法.
主要方法:
- 来自残留疾病最小的患者的转录组数据集的分析.
- 在小鼠和人类黑色素瘤模型中过度表达NR2F1.
- 评估单独使用BRAFi + MEKi和与拉巴胺素 (mTORC1抑制剂) 结合的疗效.
主要成果:
- 在最小残留疾病中,NR2F1表达升高.
- 过度表达NR2F1降低了治疗效果,抑制了增殖和侵入,并持续了mTORC1的信号传递.
- BRAFi + MEKi与拉巴胺素的联合治疗有效向耐药黑色素瘤细胞.
结论:
- NR2F1是黑色素瘤治疗耐药性的关键决定因素.
- 针对NR2F1和mTORC1信号传输,为CM患者提供了潜在的治疗策略.
- 组合疗法可以克服NR2F1和mTORC1.1介导的抗性.
相关概念视频
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
PI3K/mTOR/AKT Signaling Pathway
5.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.4K
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
The Retinoblastoma Gene
4.7K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.7K
MAPK Signaling Cascades
7.9K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.9K


